Media headlines about Cellectis (NASDAQ:CLLS) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.8263613170289 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several research firms recently weighed in on CLLS. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Cellectis in a research report on Saturday, June 3rd. SunTrust Banks, Inc. cut Cellectis from a “buy” rating to a “hold” rating and cut their price objective for the stock from $35.00 to $20.00 in a research report on Tuesday, September 5th. Nomura cut their price objective on Cellectis from $49.00 to $43.00 and set a “buy” rating for the company in a research report on Wednesday, September 6th. Zacks Investment Research cut Cellectis from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Finally, BidaskClub cut Cellectis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Cellectis has an average rating of “Buy” and an average price target of $39.00.

Cellectis (NASDAQ CLLS) opened at 27.81 on Friday. Cellectis has a 12-month low of $16.09 and a 12-month high of $30.46. The firm has a 50-day moving average price of $27.89 and a 200 day moving average price of $27.89. The firm’s market cap is $997.32 million.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at

About Cellectis

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Insider Buying and Selling by Quarter for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with's FREE daily email newsletter.